Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality

Autor: Lu Wang, Margery A. Connelly, M. Vinayaga Moorthy, JoAnn E. Manson, Akintunde O. Akinkuolie, Deirdre K Tobias, Chungying Li, I-Min Lee, Julie E. Buring, Paulette D. Chandler, Robert J. Glynn, Samia Mora, Wendy S. Post, James D. Otvos, Patrick R. Lawler, Daniel A. Duprez, David R. Jacobs, Paul M. Ridker
Jazyk: angličtina
Rok vydání: 2016
Předmět:
0301 basic medicine
Oncology
Male
Glycosylation
Glycobiology
lcsh:Medicine
Fibrinogen
Pathology and Laboratory Medicine
Biochemistry
Risk Factors
Medicine and Health Sciences
Prospective Studies
Post-Translational Modification
Prospective cohort study
lcsh:Science
Immune Response
Multidisciplinary
Incidence (epidemiology)
Incidence
Middle Aged
Prognosis
3. Good health
Survival Rate
C-Reactive Protein
Cohort
Biomarker (medicine)
Female
Colorectal Neoplasms
medicine.drug
Research Article
medicine.medical_specialty
Inflammatory Diseases
Immunology
03 medical and health sciences
Signs and Symptoms
Polysaccharides
Diagnostic Medicine
Internal medicine
medicine
Humans
Survival rate
Aged
Glycoproteins
Colorectal Cancer
Inflammation
Proportional hazards model
business.industry
lcsh:R
Case-control study
Cancers and Neoplasms
Biology and Life Sciences
Proteins
Acute Phase Proteins
United States
030104 developmental biology
Case-Control Studies
lcsh:Q
business
Biomarkers
Acute-Phase Proteins
Follow-Up Studies
Zdroj: PLoS ONE, Vol 11, Iss 11, p e0165615 (2016)
PLoS ONE
ISSN: 1932-6203
Popis: Background Acute phase proteins highlight the dynamic interaction between inflammation and oncogenesis. GlycA, a novel nuclear magnetic resonance (NMR) inflammatory marker that identifies primarily circulating N-acetyl glycan groups attached to acute phase proteins, may be a future CRC risk biomarker. Methods We examined the association between GlycA and incident CRC and mortality in two prospective cohorts (N = 34,320); Discovery cohort: 27,495 participants from Women's Health Study (WHS); Replication cohort: 6,784 participants from Multi-Ethnic Study of Atherosclerosis (MESA). Multivariable Cox models were adjusted for clinical risk factors and compared GlycA to acute phase proteins (high-sensitivity C-reactive protein [hsCRP], fibrinogen, and soluble intercellular adhesion molecule-1 [sICAM-1]). Results In WHS (median follow-up 19 years, 337 cases, 103 deaths), adjusted HRs (95% CIs) per SD increment of GlycA for CRC incidence and mortality were 1.19 (1.06–1.35; p = 0.004) and 1.24 (1.00–1.55; p = 0.05), respectively. We replicated findings in MESA (median follow-up 11 years, 70 cases, 23 deaths); HRs (95% CIs) per SD of GlycA for CRC incidence and mortality were 1.32 (1.06–1.65; p = 0.01) and 1.54 (1.06–2.23; p = 0.02), respectively, adjusting for age, sex, and race. Pooled analysis, adjusted HR (95% CI) per SD of GlycA for CRC incidence and mortality was 1.26 (1.15–1.39; p = 1 x 10−6). Other acute phase proteins (hsCRP, fibrinogen, and sICAM-1) had weaker or no association with CRC incidence, while only fibrinogen and GlycA were associated with CRC mortality. Conclusions The clinical utility of GlycA to personalize CRC therapies or prevention warrants further study. Trial Registration ClinicalTrials.gov: WHS NCT00000479, MESA NCT00005487
Databáze: OpenAIRE
Externí odkaz: